ArticleDiscover oncology2025
CD8 T cell exhaustion-associated LncRNA signature reveals novel molecular subtypes and immune targets in hepatocellular carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Terminally exhausted CD8Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) presents challenges and opportunities for immunotherapy due to its intricate immune microenvironment. Exhausted CD8 T cells (CD8Tex) are pivotal in this context but are inadequately characterized in HCC.
methodsWe conducted single-cell analysis on the GSE140228 dataset to identify key genes associated with CD8Tex in HCC. Cell communication analysis elucidated strong interactions of CD8Tex with CD8 T cells, dendritic cells (DCs), and monocytes/macrophages.
resultsPearson correlation analysis using the TCGA-LIHC dataset identified CD8Tex-associated long non-coding RNAs (lncRNAs). Utilizing univariate and multivariate Cox regression analyses, along with LASSO regression to prevent overfitting, we developed a prognostic model incorporating 5 lncRNAs. This model exhibited strong prognostic performance, and the derived risk score was validated as an independent predictor of overall survival in HCC patients. Among these lncRNAs, AL158166.1 showed the strongest correlation with CD8⁺ T cell exhaustion and was significantly associated with poor prognosis, highlighting its potential as both a biomarker and therapeutic target in HCC.
conclusionOur study not only elucidates the role of CD8Tex cells in HCC but also proposes a novel molecular classification of the disease. This classification holds promise for guiding clinical immunotherapy and precision treatments tailored to different molecular subtypes of HCC, as identified through drug sensitivity analysis. This work provides a foundational framework for advancing clinical strategies in HCC treatment and the development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.